<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-19 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-19</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-19</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <p><strong>Paper ID:</strong> paper-6033885</p>
                <p><strong>Paper Title:</strong> Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</p>
                <p><strong>Paper Abstract:</strong> OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics. The KRAS oncogene also plays an important role in the development of lung cancer. The aim of this study was to evaluate the frequency of epidermal growth factor receptor and KRAS mutations in a population of Brazilian patients with non-small cell lung cancer. METHODS: A total of 207 specimens from Brazilian patients with non-small cell lung cancer were analyzed for activating epidermal growth factor receptor and KRAS somatic mutations, and their associations with clinicopathological characteristics (including age, gender, ethnicity, smoking habits, and histological subtype) were examined. RESULTS: We identified 63 cases (30.4%) with epidermal growth factor receptor mutations and 30 cases (14.6%) with KRAS mutations. The most frequent epidermal growth factor receptor mutation we detected was a deletion in exon 19 (60.3%, 38 patients), followed by an L858R amino acid substitution in exon 21 (27%, 17 patients). The most common types of KRAS mutations were found in codon 12. There were no significant differences in epidermal growth factor receptor or KRAS mutations by gender or primary versus metastatic lung cancer. There was a higher prevalence of KRAS mutations in the non-Asian patients. Epidermal growth factor receptor mutations were more prevalent in adenocarcinomas than in non-adenocarcinoma histological types. Being a non-smoker was significantly associated with the prevalence of epidermal growth factor receptor mutations, but the prevalence of KRAS mutations was significantly associated with smoking. CONCLUSIONS: This study is the first to examine the prevalence of epidermal growth factor receptor and KRAS mutations in a Brazilian population sample with non-small cell lung cancer.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e19.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e19.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Brazilian NSCLC cohort</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Study of EGFR and KRAS somatic mutation frequencies in 207 Brazilian non-small cell lung cancer (NSCLC) patients representing all five Brazilian geographic regions; reports EGFR and KRAS frequencies and associations with clinicopathological factors.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>207 Brazilian NSCLC patients (samples submitted for EGFR/KRAS testing) representing all five Brazilian geographic regions (56.5% Southeast, 15.5% Northeast, 14.5% South, 12.1% Midwest, 1.4% North); 13 patients reported Asian ancestry and 194 non-Asian.</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>Mixed/admixed Brazilian population (predominantly non-Asian with a small Asian-ancestry subgroup; extensive admixture of Amerindian, European, African, and Asian ancestries described).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>63/207 = 30.4%</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Among EGFR-mutant cases: exon 19 deletions 38/63 = 60.3%; L858R (exon 21) 17/63 = 27.0%; exon 18 codon 719 point mutations 5/63 = 7.9%; exon 20 in-frame insertions 3/63 = 4.8%; one L861Q (exon 21). (Percentages are relative to EGFR-mutant subset.)</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Smoking data available for 162 patients: 88 never-smokers and 74 current/ex-smokers (88/162 = 54.3% never-smokers; 74/162 = 45.7% current/ex-smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>EGFR mutations significantly enriched in never-smokers: 45.5% of never-smokers had EGFR mutations vs 18.9% of current/ex-smokers (Chi-square p < 0.001 as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Smoking (tobacco) discussed as an environmental factor; KRAS G->T (G12C, etc.) substitutions attributed to polycyclic aromatic hydrocarbons in tobacco smoke. No other population-level environmental exposures (e.g., cooking fumes, air pollution) were reported in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>No specific germline variants or SNPs were reported; authors propose genetic background/admixture as a likely contributor to population-level differences but do not identify particular germline alleles.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Authors compare their observed EGFR frequency (30.4%) to ranges reported in other populations: Asians 27-60% (multiple citations), Europeans 8-13%, and African and white Americans 12-16%; they note the Brazilian rate is higher than Europeans/Americans and close to reported Asian rates. For KRAS, literature ranges cited: Caucasians 20-30% vs Asians 5-20%; in this cohort KRAS frequency was 30/206 = 14.6% and all detected KRAS mutations occurred in non-Asian patients (13 Asian patients in cohort).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Authors favor a genetic background (ancestry/admixture) explanation for higher EGFR mutation frequency rather than primarily environmental causes; they also discuss smoking-related mutagenesis (PAHs) as contributing to KRAS mutation patterns. They explicitly state prior reports found no clear geographic associations, supporting genetic rather than environmental explanations.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>EGFR-mutant tumors were predominantly adenocarcinomas (33.7% EGFR mutation frequency in adenocarcinoma vs 15.8% in non-adenocarcinoma), enriched in never-smokers, and showed a non-significant tendency to be more common in females (33.3% in females vs 26.4% in males); no significant associations with age groups (>45 vs â‰¤45) or primary vs metastatic status.</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Small number of patients reporting Asian ancestry (n=13) limits power to detect ethnic differences; specimens were those submitted for mutation testing (potential selection bias); incomplete smoking data for some patients; ethnicity information derived from pathology request forms (possible misclassification); heterogeneous admixture within Brazil complicates attribution to specific ancestral components.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Sample represents all five Brazilian macroregions but the paper does not present EGFR frequency stratified by Brazilian region; authors cite literature saying no geographic associations have been found in prior studies comparing populations, implying observed ethnic differences are genetic rather than environmental.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e19.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>East Asian populations (literature ranges)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>East Asian patients with NSCLC (as reported in cited literature)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced literature reports substantially higher EGFR mutation frequencies in East Asian NSCLC patients compared with Western populations; EGFR mutations are associated with adenocarcinoma histology and never-smoking status in these populations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Aggregate/literature-reported East Asian NSCLC cohorts (ranges cited in this paper, not a single cohort within this study).</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>East Asian (broad category; specific nationalities not enumerated in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported literature range cited in this paper: approximately 27% to 60% (other phrasing in discussion: ~30-50% in Asians).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Paper cites that exon 19 deletions and exon 21 L858R substitutions are the most common activating EGFR mutations in these populations (no Asia-specific breakdown provided in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Other literature generally shows enrichment of EGFR mutations in never-smokers; the paper cites that EGFR-mutant lung cancers are prevalent among non-smokers in Asian reports.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>EGFR mutations described in cited literature as more common in never-smokers (paper cites multiple studies establishing this association).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>No specific environmental exposures beyond smoking were cited in relation to East Asian rates in this paper; authors note that prior studies found no geographic associations suggesting environmental causes are less likely.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>Authors cite the idea that genetic background (ancestry) likely contributes to higher EGFR mutation prevalence in East Asians but no specific germline variants are provided in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Compared in text to Europeans (8-13%) and African/white Americans (12-16%); East Asian rates substantially higher per cited literature ranges.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Paper relays the hypothesis from prior studies that population (East Asian) differences are driven by genetic susceptibility/ancestry rather than environmental factors.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Literature-cited profile: younger, female, never-smokers, adenocarcinoma histology (as a common clinical profile of EGFR-mutant tumors in East Asians).</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Paper notes that geographic vs genetic contributions are debated; does not provide additional confounder analysis for Asian cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Described broadly as 'Asian' in cited literature; no within-Asia geographic breakdown provided in this paper.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e19.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>European populations (literature ranges)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>European NSCLC patients (as reported in cited literature)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced literature reports lower EGFR mutation frequencies in Europeans compared with East Asians; cited range in this paper is approximately 8-13%.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Aggregate/literature-reported European NSCLC cohorts (ranges cited in this paper; no single European cohort analyzed here).</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>European/White (broad category).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported literature range cited in this paper: ~8% to 13%.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Paper notes exon 19 deletions and L858R are the most common activating EGFR mutations generally, but does not provide European-specific mutation spectra in this text.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Not specifically delineated for European cohorts in this paper; in general EGFR mutations are associated with never-smokers across populations per cited literature.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>Cited literature supports EGFR enrichment in never-smokers; no Europe-specific numbers provided in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Not specified for European cohorts in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>Authors imply lower frequency in Europeans is consistent with ancestry-related genetic differences but no loci are reported here.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Compared to Asian cohorts (higher EGFR frequency) and Brazilian cohort (Brazilian observed frequency higher than typical European ranges).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Paper relays that genetic background/ancestry likely influences EGFR prevalence differences between Europeans and Asians.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Not specified in detail for Europeans in this paper beyond general EGFR-associated profile from literature (adenocarcinoma, never-smoker, female).</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Paper does not list Europe-specific confounders; general concerns about geographic vs genetic contributions noted.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>No within-Europe geographic breakdown provided in this paper.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e19.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>African and white American populations (literature ranges)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>African and white American NSCLC patients (as reported in cited literature)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper cites literature giving EGFR mutation frequency estimates for African and white American patients as approximately 12-16% and notes differences in KRAS frequencies across ethnic groups.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Aggregate/literature-reported African and white American NSCLC cohorts (ranges cited in this paper; no single cohort analyzed here).</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>African American and White American (broad categories).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported literature range cited in this paper: ~12% to 16% (for African and white Americans combined as cited).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Not detailed in this paper for these populations; general comment that exon 19 deletions and L858R are the most clinically relevant and common worldwide.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Not specifically broken down for these groups in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>The general association of EGFR mutations with never-smokers is cited in the literature; no group-specific quantified association provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Not specified in relation to these groups in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>No specific germline variants reported; differences are discussed qualitatively as likely ancestry-related.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Compared in text to higher Asian EGFR frequencies (27-60%) and to the Brazilian cohort which had higher EGFR frequency than these US/European ranges.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Authors mention genetic background (ancestry) as a likely contributor to differing EGFR frequencies; specific mechanisms in African or white Americans not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Not provided in detail for these populations within this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Paper does not detail confounders specific to African/white American studies; general caveats about study heterogeneity apply.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Not discussed for within-US geographic variation in this paper.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e19.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Caucasian populations (KRAS literature)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Caucasian NSCLC patients (KRAS mutation literature cited)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Paper cites literature reporting higher KRAS mutation frequencies in Caucasian lung adenocarcinoma patients (20-30%) compared with Asian patients (5-20%), and discusses smoking association with KRAS mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Aggregate/literature-reported Caucasian lung adenocarcinoma cohorts (reported ranges cited in this paper; not analyzed directly here).</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>Caucasian/European ancestry (broad category).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Cited literature indicates KRAS mutations are strongly associated with tobacco smoking in these cohorts; EGFR mutations more common in never-smokers per broader literature.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Smoking (tobacco) highlighted as a cause of KRAS G->T transversions via polycyclic aromatic hydrocarbons; no other environmental factors specified in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>Not specified; paper discusses ethnic differences qualitatively without naming germline markers.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>KRAS: cited ranges for Caucasians 20-30% vs Asians 5-20%; in the Brazilian cohort KRAS frequency was 14.6% and KRAS mutations were found exclusively in non-Asian patients in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Authors link KRAS mutation spectrum (e.g., G12C) to tobacco-related PAH mutagenesis; population differences in KRAS frequency implied to be related to differential smoking exposures and possibly genetic background.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>KRAS mutations associated with smoking and occur mainly in adenocarcinoma patients per cited literature; in this Brazilian cohort, smokers were 2.7x more likely to have KRAS mutations than non-smokers.</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Heterogeneity of smoking histories, population structure, and study inclusion criteria across the cited literature could confound direct comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>No fine-grained geographic breakdown provided in this paper for KRAS across Caucasian populations.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib <em>(Rating: 2)</em></li>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer <em>(Rating: 2)</em></li>
                <li>KRAS mutations and resistance to EGFR-TKIs treatment in patients with nonsmall cell lung cancer: a meta-analysis of 22 studies <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>